On Thursday, AbbVie Inc. (NYSE:ABBV) reported second-quarter 2025 sales of $15.42 billion on Thursday, beating the consensus ...

Q2 2025 Earnings Call Transcript July 31, 2025 AbbVie Inc. beats earnings expectations. Reported EPS is $2.97, expectations ...

AbbVie Inc. is in talks to acquire next-generation psychedelics developer Gilgamesh Pharmaceuticals, according to people ...

AbbVie Inc (ABBV) surpasses expectations with robust sales from Skyrizi and Rinvoq, while navigating Humira declines and ...

AbbVie has reported topline outcomes from the first of two trials of the Phase III UP-AA programme, assessing Rinvoq (upadacitinib).

NORTH CHICAGO, Ill. (AP) — NORTH CHICAGO, Ill. (AP) — AbbVie Inc. (ABBV) on Thursday reported second-quarter earnings of $938 million. The North Chicago, Illinois-based company said it had net income ...

According to the update, the $823 million expense is related to acquired IPR&D, typically incurred through collaborations, ...

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

A Delaware federal jury said on Friday that Revance Therapeutics owes AbbVie's Allergan Inc $56 million after finding that ...

This was the stock's third consecutive day of losses.

AbbVie Inc. (NYSE: ABBV) is reportedly negotiating the acquisition of Gilgamesh Pharmaceuticals, a privately held mental ...